Abstract
Various methods [fluorescent polarization immunoassay (FPIA) and liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) assay] are used for therapeutic drug monitoring of everolimus. The aim of this study is to compare these assays in renal and heart transplantation. The correlation between results was investigated by linear regression in 44 patients (24 heart recipients and 20 renal recipients—137 samples). The comparison between assays was performed by a paired t‐test. A highly significant correlation was found between FPIA and LC‐MS/MS in heart and renal recipients [FPIA=0.851 × LC‐MS/MS+1.773r 2=0.8738 (P<0.001)]. Paired t‐tests did not show a significant difference between everolimus whole blood concentrations in the populations of heart and renal recipients or heart recipients or renal recipients. FPIA and LC‐MS/MS assays gave consistent overall results although some significant differences were observed in some samples between these methods indicating that FPIA assay has limitations that deserve further investigations. J. Clin. Lab. Anal. 22:282‐285, 2008. © 2008 Wiley‐Liss, Inc.
Keywords: everolimus, chromatography, therapeutic drug monitoring, immunoassay
REFERENCES
- 1. Dunn C, Croom KF. Everolimus: A review of its use in renal and cardiac transplantation. Drugs 2006;66:547–570. [DOI] [PubMed] [Google Scholar]
- 2. Oellerich M, Armstrong VW. The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy: Recent developments. Ther Drug Monit 2006;28:720–725. [DOI] [PubMed] [Google Scholar]
- 3. Khoschsorur G, Fruehwirth F, Zelzer S, Stettin M, Halwachs‐Baumann G. Comparison of fluorescent polarization immunoassay (FPIA) versus HPLC to measure everolimus blood concentrations in clinical transplantation. Clin Chim Acta 2007;380:217–221. [DOI] [PubMed] [Google Scholar]
- 4. Baldelli S, Crippa A, Gabrieli R, et al Comparison of the Innofluor certican assay with HPLC‐UV for the determination of everolimus concentrations in heart transplantation. Clin Biochem 2006;39: 1152–1159. [DOI] [PubMed] [Google Scholar]
- 5. Salm P, Warnholtz C, Boyd J, Arabshahi L, Marbach P, Taylor PJ. Evaluation of a fluorescent polarization immunoassay for whole blood everolimus determination using samples from renal transplant recipients. Clin Biochem 2006;39:732–738. [DOI] [PubMed] [Google Scholar]
- 6. Koal T, Deters M, Casetta B, Kaever V. Simultaneous determination of four immunosuppressants by means of high speed and robust on‐line solid phase extraction‐high performance liquid chromatography‐tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004;805:215–222. [DOI] [PubMed] [Google Scholar]
- 7. Strom T, Haschke M, Boyd J, et al Crossreactivity of isolated everolimus metabolites with the Innofluor Certican immunoassay for therapeutic drug monitoring of everolimus. Ther Drug Monit 2007;29:743–749. [DOI] [PubMed] [Google Scholar]
- 8. Taylor PJ. Internal standard selection for immuno‐suppressant drugs measured by high‐performance liquid chromatography tandem mass spectrometry. Ther Drug Monit 2007;29:131–132. [DOI] [PubMed] [Google Scholar]
- 9. Hoogtanders K, van der Heijden J, Stolk LM, Neef C, Christiaans M, van Hooff J. Internal standard selection for the high‐performance liquid chromatography tandem mass spectroscopy assay of everolimus in blood. Ther Drug Monit 2007;29:673–674. [DOI] [PubMed] [Google Scholar]